Mesoblast Ltd
Research Mesoblast Ltd (MESO) on Bullrun: market cap USD 2.20B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMESO
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.20B
- Financial periodFY2025
- Free cash flow-USD 60.75M
Valuation Snapshot
latest market cap is USD 2.20B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | -USD 60.75M | n/a | n/a | USD 129.57M | USD 135.14M | USD 574.68M |
| FY2024 | n/a | n/a | -USD 42.77M | n/a | n/a | USD 37.66M | USD 126.11M | USD 461.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.20B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.31B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.28B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 188.79M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 452.13M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 656.26M | n/a | n/a | n/a |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mesoblast Ltd's market cap?
Mesoblast Ltd's market capitalization is USD 2.20B.
What does Mesoblast Ltd do?
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.